The aim of this article is to provide an inventory of the use of contrast-enhanced ultrasound (CEUS) in relation to percutaneous interventional procedures. The article is structured into a systematic literature review followed by a clinical part relating to percutaneous CEUS-guided procedures. A literature search identified 3109 records. After abstract screening, 55 articles were analyzed and supplemented with pictorial material to explain the techniques. In conclusion, the best-evidenced indications for CEUS-guided interventions are biopsy and ablation of inconspicuous or Bmode-invisible tumors, intraprocedural ablation control and follow-up, as well as percutaneous transhepatic cholangiography and drainage procedures.
T his article describes the use of contrast-enhanced ultrasound (CEUS) in relation to percutaneous interventional procedures. The intention is to present a systematic review accompanied by a commented inventory of available indications and techniques based on published material and personal experience supported by pictorial examples.
Throughout the last 2 decades, the international US community has witnessed an increasing interest in CEUS. [1] [2] [3] [4] Unlike other contrast-enhanced imaging modalities such as magnetic resonance imaging (MRI) and computed tomography (CT), a CEUS study can be performed despite impaired renal function, and it rarely requires sedation and involves no radiation exposure. In addition, allergic and severe adverse reactions are rare, reported in around 1 per 10,000 patients. 5 The first clinical CEUS guideline was published in 2004 and described the use of CEUS for detection and characterization of focal liver lesions in adults and for monitoring percutaneous tumor ablation. Contrary to CT and MRI, a CEUS study is a real-time examination that is especially advantageous for evaluation of focal liver lesions. Contrast uptake may vary, which can lead to ambiguity on CT in, for example, hemangiomas if the characteristic contrast uptake pattern and centripetal filling-in are over and done already in Videos online at jultrasoundmed.org the arterial phase. Contrast-enhanced US allows realtime imaging of the contrast uptake and, in addition, repeated visualization of the filling behavior of a lesion by bursting the contrast microbubbles in the image field. It is the exact same real-time aspect of CEUS that makes it so uniquely suited for interventions. Image modalities such as positron emission tomography-CT and MRI with liver-specific contrast greatly improve the sensitivity for detection of malignant liver lesions. However, they may also generate false-positive findings, and in either scenario, a biopsy may be required before further therapy is instituted. Contrast-enhanced US can potentially become a pivotal factor to help locate the lesion and enable CEUS-guided biopsy.
This article is structured into an overall literature review part followed by a clinical part with 3 main sections based on indications for the use of CEUS: (1) CEUS-guided biopsy; (2) CEUS in relation to USguided tumor ablation; and (3) CEUS for intracavitary use and miscellaneous indications. Each section contains a systematic review of the literature accompanied by clinical and pictorial material to explain the technique in question.
For practical considerations related to the interventions per se, any CEUS-guided intervention can be performed like the routine US-guided version of the procedure. In some cases, it may be necessary to use 2 contrast agent injections: 1 to plan the procedure and a second to perform it. Alternatively, an infusion pump may be used with continuous infusion throughout the procedure.
Methods
The systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. 6 A protocol of the review was registered at PROSPERO 7 with registration number CRD42016036862 (PROSPERO International Register of Systematic Reviews; University of York, Centre for Reviews and Dissemination, York, England; 2017; http://www.crd.york.ac.uk/PROSPERO/).
PubMed, Scopus, and Cochrane databases were searched on May 16, 2017 . The search string for PubMed was ("interventional ultrasonography" [MeSH] or "interventional ultrasonography" or "interventional ultrasound" [MeSH] or "interventional ultrasound" or "interventional US" or "ultrasound guided biopsy" or "ultrasound guided ablation") and ("contrast media" [MeSH] or "contrast enhanced" or "contrast"). The search terms were modified to fit Scopus: ("interventional ultrasonography") and TITLE-ABS-KEY ("contrast enhanced" or "contrast media"); and Cochrane: ("interventional ultrasonography" or "interventional ultrasonography" or "interventional ultrasound" or "interventional US" or "ultrasound guided biopsy" or "ultrasound guided ablation") and ("contrast media" or "contrast enhanced" or "contrast").
The Covidence online platform (http://www.covidence.org) was used for screening and selection. Covidence includes a blinded review and selection process in which agreement between at least 2 authors is necessary to make a decision concerning inclusion of a study. The authors were blinded to other authors' decisions. Duplications in titles and abstracts were removed, and 2 of the authors independently performed title and abstract screening and subsequent full-text screening. Any discrepancies were solved by discussion. Only clinical studies with available full text in English or German were included. All articles that met these inclusion criteria were obtained as full text. We included studies investigating US-guided interventional procedures or complications related to such procedures. The studies should have evaluated the benefit of using US contrast agents during the procedure for guidance or temporally in close proximity to the procedure to improve the outcome, estimate the result, or investigate possible complications. Included studies were articles reporting on any procedure in which CEUS was applied for 1 or more of the above-mentioned purposes. To be included, the studies had to report the success rate of the procedure or at least an estimate if the technique was practically feasible. In addition, studies estimating the feasibility of CEUS for evaluation and guidance of percutaneous treatment of complications of US-guided interventional procedures, especially bleeding, were included. Studies of interest were randomized trials, cohort and case-control studies, and case series.
A quality assessment of outcomes derived from the included articles was attempted. as recommended by the Cochrane Collaboration. 8, 9 For each of the 3 sections in the clinical part, a separate summary with conclusions on the relevant CEUS indications is provided including, when applicable, an estimate of the level of recommendation that can be applied to this particular use of CEUS. For this purpose, we used the systematic approach developed by the Oxford Centre for Evidence-Based Medicine (http://www.essentialevi denceplus.com/product/ebm_loe.cfm?show 5oxford) 10 as adapted and implemented by the European Federation of Societies for Ultrasound in Medicine and Biology (Table 1) . 4, 11, 12 Results A total of 3109 records were found. After abstract screening, 84 articles were identified for full-text screening, which resulted in 55 articles finally included ( Figure  1 ) in the 3 categories. Regarding meta-analysis, most of the included articles were case series or case-control studies, many with a retrospective design, and the material overall had such a degree of heterogeneity that it was considered meaningless to perform a meta-analysis. 13 Contrast-Enhanced US-Guided Biopsy Contrast-enhanced US has a number of obvious applications related to US-guided biopsy and may in some cases even be indispensable, yet the literature is limited. In this systematic review, potential indications for CEUSguided biopsy were divided into 3 main categories: (1) biopsy from perfused areas to avoid necrosis; (2) biopsy of poorly visualized or downright "invisible" lesions; and (3) additional benefits from CEUS in relation to USguided biopsy. A total of 19 articles were identified. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Biopsy From Perfused Areas to Avoid Necrosis Frequently, the pathologic report from a liver lesion biopsy or other abdominal mass biopsy may simply read as necrotic material. A repeated procedure is then warranted to obtain decisive material, and increased attention is paid to avoid sampling from necrotic areas within the lesion.
With CEUS, tissue viability can be evaluated effectively. By directing the biopsy needle toward contrastenhanced areas within the target lesion, inadvertent sampling from necrotic parts of the tumor can be reduced. This strategy resulted in a 10% to 15% increase in diagnostic accuracy by a decrease in the false-negative rate. [14] [15] [16] 20, 21, 23, [25] [26] [27] [28] [29] 31, 32 The principle of this technique was first described in 2000 by Bang et al, 14 in a small feasibility study using Levovist (Schering AG, Berlin, Germany) and real-time sampling from enhancing areas. In 2006, Wu et al 23 published a prospective single-center randomized trial that enrolled 186 patients with suspected liver metastases. Patients were randomized to US or CEUS using SonoVue (Bracco SpA, Milan, Italy) for prebiopsy scanning to identify the optimal biopsy target. They reported a statistically significant increase in the diagnostic accuracy of the initial biopsy for small 27, 31 The patients, 90 in the mediastinal study and 181 in the liver study, were referred for percutaneous biopsy, prospectively included, and randomized to the US-or CEUS-guided technique. The final diagnosis was derived from surgical biopsy or 6 months of clinical and imaging follow-up. The results were significantly better in the CEUS group, with an increase in correct diagnoses of 13% to 15%. Noteworthy, in the liver study, 10 of 15 patients in the non- CEUS arm with negative pathologic results were rebiopsied with CEUS guidance, and in all cases, a malignant diagnosis was reached. 31 The same concept of targeting contrast-enhanced tissue, assuming viability, has been applied in settings for biopsy of various liver, lung, mediastinum, neck, musculoskeletal, undetermined abdominal, and other tumors with encouraging results and reported feasibility of 94% to 100%. [15] [16] [17] 20, 21, 25, 26, 28, 32 These studies were all single-center nonrandomized case series, and many were retrospective studies. Three articles reported a case-control study design with historic matching control groups in comparable studies trying to avoid necrotic areas in lung and mediastinal biopsy. 15, 21, 28 Their material consisted of 121, 142, and 252 patients, respectively, with each consisting of 2 approximately equally sized groups. The first group comprised patients referred for biopsy in the era before CEUS; thus, all had routine B-mode US-guided biopsy. In the second group, all biopsies were guided by the findings of prebiopsy CEUS scanning; thus, the biopsy per se was not done with real-time CEUS guidance. All 3 studies reported an increase in the success rate with CEUS guidance compared to B-mode US, and CEUSguided biopsy reached diagnostic success rates in the range of 93.6% to 98.3%. 15, 21, 28 "Feasibility rate," "technical effectiveness rate," "technical success rate," or similar words appear in most articles as a measure of the technical ability of doing the investigated technique. There are, however, large variations in both definitions and terminology, and the data cannot be pooled. Several studies, including 5 prospective case series with 20 to 171 patients and 1 retrospective study of 115 patients, investigated CEUS-guided biopsy of soft tissue masses and reported feasibility rates ranging from 94.7% to 100% with regard to obtaining a correct histologic diagnosis. 16, 17, 20, [29] [30] [31] Figure 2 and Video 1 show CEUS-guided biopsy from a contrastenhanced presumably viable area inside a large tumor with necrosis.
Biopsy of Poorly Visualized or Invisible Lesions
Focal indeterminate lesions diagnosed on CT, MRI, or positron emission tomography-CT may be referred for US-guided biopsy for final diagnosis. However, with Bmode US, no lesion may be identified, or the lesion is not satisfactorily conspicuous for a biopsy. In both clinical scenarios, CEUS may be helpful in 2 different ways: (1) the target lesion identified on previous imaging may turn from invisible or just inconspicuous on B-mode US imaging to "clearly visualized" on CEUS imaging; and (2) additional lesions potentially rendering themselves more easily accessible for biopsy may be visualized and biopsied under CEUS guidance.
This concept was introduced in 2002 by Skjoldbye et al 30 in a prospective case series of 30 oncologic patients with the use of Levovist and the now-obsolete technique of intermittent scanning during pulse inversion US imaging of inconspicuous liver lesions suspected of malignancy. Contrast-enhanced US showed new lesions in 60%, and real-time contrast-guided biopsy confirmed metastases in 100%, with a high impact on patient treatment, avoiding unnecessary surgery in 47% of patients, who would have been inoperable. In 2004, Schlottmann et al 18 refined the technique using SonoVue and real-time CEUS in a small retrospective case series of 12 patients with invisible liver lesions on routine US imaging. The study reported a CEUS-guided success rate of 91%. The same principle was applied 6 years later in a prospective nonrandomized feasibility study of 44 patients with invisible liver lesions. 24 An inclusion criterion was that previous attempts to perform US-guided biopsy with B-mode imaging was impossible because of nonvisualization by 2 experienced radiologists of the target lesion seen on other imaging modalities. The reported success rate of CEUS-guided biopsy was 86%. In a similar prospective feasibility study of 53 patients with pancreatic lesions that were not sufficiently visualized to allow for routine B-mode US-guided biopsy, a satisfactory percutaneous biopsy rate of 96.2% was achieved. 22 In a prospective study investigating use of the contrast agent Sonazoid (GE Healthcare, Chalfont St Giles, England) for Kupffer cell-phase imaging with real-time guidance, the lesion detection rate for intraindividual comparison was increased from 77.3% with Bmode US to 92.0% with CEUS, with a 95.2% technical success rate for CEUS-guided biopsy of these lesions. 29 Finally, in the randomized liver lesion study mentioned above, for the subset of patients with negative B-mode guided biopsy results, in 25%, the reason was poor visualization of the lesions, and CEUS-guided rebiopsy in all cases reached a malignant diagnosis.
31 Figure 3 and Video 2 show CEUS-guided biopsy from a B-modeinvisible liver lesion.
Additional Benefits From CEUS in Relation to US-Guided Biopsy
In addition to the above-mentioned indications, CEUS may be beneficial in relation to interventional US in terms of the following: 1. Avoiding biopsy from lesions if a CEUS study unequivocally shows a benign lesion (eg, focal nodular hyperplasia or hepatic hemangioma), and CEUS may thereby potentially reduce morbidity and complication rates. 2, 3, 11, 12 The first two referenced articles (Refs 2 and 3) are the worldwide CEUS liver guidelines. Obviously, these articles do not concern CEUS-guided procedure per se but rather reflect a scenario in which CEUS provides the diagnosis of a lesion without percutaneous biopsy. The scientific evidence to support this idea is substantial. In addition to CEUS guidelines and the literature these are based on, articles in the form of both meta-analyses and systematic reviews support this CEUS feature. [33] [34] [35] [36] Contrast-enhanced US for characterizing a focal liver lesion represents the most widespread use of CEUS, in which the procedure is performed to characterize a lesion found on another imaging study such as CT, MRI, or conventional US, thereby substituting for a percutaneous biopsy. 2. Improve breast cancer staging by identifying and guiding biopsy of sentinel nodes after intradermal contrast agent injection when axillary B-mode findings are normal.
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Contrast-Enhanced US-Guided Biopsy: Conclusions Contrast-enhanced US has many advantages relating to US-guided biopsy (Table 2) , and the benefits of the above-mentioned CEUS-assisted biopsy techniques are so obvious that it is understandable why they are rapidly Figure 3 . Contrast-enhanced US-guided biopsy of a B-mode-invisible liver lesion in a 67-year-old male patient with newly diagnosed colon cancer and suspected liver metastases on previous CT. The patient was referred for US-guided biopsy before chemotherapy. However, no obvious lesion could be identified on routine B-mode US imaging. A, Baseline CEUS examination shows a clearly suspicious lesion in the right liver lobe, which was easily accessible for CEUS-guided biopsy. B, Planning for the biopsy is indicated by the electronically displayed puncture line. C, Since the lesion was invisible on B-mode imaging, a second SonoVue injection was done approximately 12 minutes after the baseline CEUS scanning. Timing of the 2 injections is indicated in left lower corner. When the lesion was clearly visualized at approximately 1 minute after contrast agent injection due to wash-out of the contrast agent, a 1.2-mm Tru-Cut histologic needle biopsy was performed as a real-time CEUS-guided procedure.
gaining widespread use. The benefits of being able to direct a biopsy toward an otherwise invisible target stand undisputed and do not need further proof. This principle applies both when the problem concerns a viable contra necrotic tissue scenario ( Figure 2 and Video 1) and when it is caused by lack of acoustic differences between healthy and pathologic tissue ( Figure 3 and Video 2). Scientific evidence for real-time CEUS-guided biopsy is somewhat limited, with no multicenter studies and only 3 randomized studies published on the subject, with most being either case series or case-control series. Despite this sparseness of publications, there is enough evidence for the category "CEUS-guided biopsy of poorly visualized or invisible lesions" to be recommended with a grade of recommendation of A: ie, "recommendation based on good evidence" (Table 1 ), because 6 studies tested US guidance versus CEUS guidance in a set of patients, all of whom underwent both the diagnostic test (ie, CEUS-guided biopsy) and the reference standard (ie, attempted US-guided biopsy, which was unsuccessful because of invisibility of the biopsy target; Table 2 ). The reported increase in success rates from impossible to do (ie, 0%) without CEUS assistance to CEUS-guided values of 86% to 100% of cases must be considered nothing less than simply overwhelmingly good evidence.
With respect to CEUS for US-guided biopsy to avoid necrotic areas in liver biopsy and the other uses described, the grade of recommendation that can be assigned is B: "recommendation based on moderate evidence" (Table 1 ). To reach a higher grade, studies enrolling an appropriate number of patients, all of whom have undergone both the diagnostic test and the reference standard, must be conducted, similar to the case for biopsy of inconspicuous lesions, and so far, no studies with intraindividual comparisons have been published. Regarding the clinical category of "additional benefits from CEUS in relation to US guided biopsy," a grade of A can be assigned for avoiding biopsy by CEUS characterization and a grade of B (based on moderate evidence) for the remaining clinical indications (Table 2) .
Contrast-Enhanced US-Guided Tumor Ablation
This indication is by far the largest subsection of CEUS-guided procedures, and the use of CEUS in this regard falls into 3 categories: (1) CEUS 
Contrast-Enhanced US Visualization of the Ablation Target
Several authors mention the use of CEUS for preablation evaluations; however, not all reports provide further details or metrics on this parameter. Eleven studies specifically reported their results with percutaneous CEUSguided ablation of hepatic malignancies, which were either poorly visualized or not seen on conventional US imaging. 7, 10, 29, 37, 42, 44, [48] [49] [50] [51] 53 In 75% to 98% of cases, CEUS was reported to visualize and guide ablation of hepatocellular carcinoma that was previously invisible or inconspicuous on conventional US imaging. 10, 42, 44, [48] [49] [50] [51] For metastatic disease, it was found that in 13% of the cases, CEUS revealed further ablation targets missed on conventional US examinations. 7 Regarding patient populations with mixed liver malignancies, an increase in the lesion detection rate from 27% with conventional US to 95% with CEUS was reported. 37 Another study found an increased detection rate from 73% with conventional US to 100% with CEUS during the course of planning ablation procedures. 53 In a prospective study of radiofrequency (RF) ablation of 52 consecutive hepatocellular carcinoma tumors, an increase in the detection rate from 57% with conventional US to 96% with CEUS was found (P < .01). 48 Specifically for the use of Sonazoid and so-called postvascular or Kupffer cell-phase imaging, for guidance of ablation or biopsy of hepatic malignancies, an overall increase in lesion detection of 15% was reported in a prospective study of 75 patients. Forty-four percent of the patient population, however, had only biopsy performed, and the reported data did not separate between the two. 29 Figure 4 and Video 3 show a preprocedural CEUS assessment during ablation of liver metastasis.
Intraprocedural Guidance and Immediate Postablation Evaluation With Intention to Reablate
Eleven studies reported feasibility or technical success rates for CEUS-guided percutaneous ablation in the range of 92% to 100%, and the rates of clinical or technical effectiveness, which was defined as immediate complete tumor necrosis, were 90% to 100%. 37, [41] [42] [43] [47] [48] [49] [50] [51] 55, 56 Regarding immediate postablation assessments of treatments, a remarkably high benefit of CEUS was reported in a prospective feasibility study of 22 mixed liver malignancies using intraprocedural and immediate postablation CEUS assessments of tumor ablation during CT-guided RF ablation. Immediate postablation CEUS detected 10 of 11 cases with residual tumors, and only 1 of these 11 cases was visible on immediate postablation CT. Overall, intraprocedural CEUS led to a change in therapeutic management in 59% of cases, resulting in 17 additional ablation cycles with resulting complete ablation in all cases. 53 A retrospective study evaluated the benefit of CEUS with SonoVue 5 to 10 minutes after assumed completion of 93 consecutive patients with hepatocellular carcinoma and a total of 148 ablations. 45 In 36.5% of cases, residual viable tumors were found, which led to immediate additional ablation treatments until complete necrosis on CEUS was achieved. Computed tomography or MRI at 24 hours after ablation showed complete ablation in 95% of the cases, thus demonstrating an added value of CEUS of 31.1% in clinical effectiveness.
Similarly, a retrospective study evaluated the ability of CEUS to provide essential intraprocedural feedback with an increase in ablation success due to marked reduction in the occurrence of residual viable tumors. 57 Sixty-four ablations were performed in 2 groups of patients. Group 1 underwent a standard ablation procedure with CT or US guidance. In addition to the identical protocol, group 2 also had immediate intraprocedural CEUS guidance, and the ablation procedure was continued until CEUS indicated complete ablation. Six of 64 ablations had viable residual tumor tissue, with 16.7% in the routine protocol group and 0% in the postablation CEUS-evaluated group (P 5 .023). In Figure 5 and Video 4, intraprocedural CEUS guidance during microwave ablation shows a lesion to be avascular due to coagulation caused by the ablation procedure.
Ablation Evaluation and Follow-up
In a prospective case-control study of 90 hepatocellular carcinomas treated with percutaneous ablation, using either RF or ethanol, the finding of an avascular pattern on CEUS imaging immediately after ablation with RF was highly predictive of therapeutic success in terms of complete necrosis on CT at a 1-month follow-up, with sensitivity of 100% and a positive predictive value of 89%. Contrast-enhanced US after percutaneous ethanol ablation was less accurate, with sensitivity of 75% and a positive predictive value of 72%. 38 A similar study with a prospective design but with nonconsecutive patient enrollment found that postprocedural CEUS allowed prediction of residual disease at a 1-month follow-up with CT or MRI in 90% of patients. 54 Furthermore, the authors found that CEUS examinations that were repeated at the time of follow-up agreed with findings of the relevant CT or MRI in 95% of patients.
A retrospective study reported results concerning residual tumor detection with immediate and 24-hour postprocedural CEUS examinations plus 24-hour follow-up CT. 46 The accuracy parameters of these 3 imaging events were not significantly different from one another and correctly predicted the 3-month follow-up imaging findings in 79% to 85% of the cases. Specifically, regarding the presence of residual tumors, sensitivity was 33% to 42%, and specificity was 92% to 97%.
A similar study, however, using CEUS and MRI for 24-hour postprocedural evaluations found sensitivities and specificities for residual tumor tissue detection on day 1 of 100% and 83% for CEUS and 87% and 67% for MRI, respectively. 58 These figures were not statistically significant; however, they were extremely valuable and Figure 5 . Intraprocedural CEUS during microwave ablation in a 64-year-old female patient with a diagnosis of solitary metastasis from colorectal cancer. A CEUS assessment of liver metastasis immediately after ablation had been terminated. B-mode image on the left shows the 2 microwave antennas still located in the lesion just after ablation.The lesion appears echogenic due to microbubbles caused by the heat from the ablation procedure. Image on the right, the CEUS mode, shows the lesion to be avascular due to coagulation caused by the ablation procedure.
important for potential reablation, as CEUS, in contrast to MRI, had no false-negative findings. Last, in a 1999 prospective case series, as one of the first articles in this field, Solbiati et al 52 evaluated RF ablation of colorectal liver metastases 24 hours after treatment with US, CEUS, and CT. Ultrasound found no residual foci; however, CEUS showed incomplete ablation in 15% of cases and showed 85% diagnostic agreement with CT.
In a slightly different design, 79 patients with a total of 83 renal cell carcinomas were enrolled in a prospective study of CEUS after microwave ablation with the reference standard being a combination of CT/MRI and clinical follow-up for evaluating the therapeutic effect. 40 Contrast-enhanced US examinations were performed on the third day after ablation and at every 3-month followup and compared to either CT or MRI, with reported sensitivity of 86% to 100%, specificity of 97% to 99%, and diagnostic accuracy of 97% to 98%. Figures 6 and 7 and Videos 5 and 6 show microwave ablation of hepatocellular carcinoma. In Figure 6 and Video 5, a CEUS evaluation shows complete ablation at the 24-hour follow-up. In Figure 7 and Video 6, an immediate postablation evaluation with CEUS shows residual viable tissue and enables CEUS-guided reablation in the same session. Repeated CEUS after the second ablation showed complete ablation.
Contrast Enhanced US-Guided Ablation: Conclusions
There are great differences in the purpose, design, and evaluated quality of the articles included in this section. The available literature, however, provides a strong indication that CEUS has a major role to play in all aspects of US-guided ablation (Table 2) . It is also true from our personal experience. We use CEUS in preablation evaluations and procedure planning (Figure 4 and Video 3), in placement of ablation needles in the tumors, and in immediate postablation control of tumor necrosis as well as in the long-term follow-up regimen ( Figures 5-7 and Videos 4-6). Although part of this algorithm may be replaced by different imaging modalities, others cannot easily be subject to this because of the inherent realtime feature of CEUS. Thus, it is evident from the literature that CEUS is valuable in all 3 aspects of percutaneous ablation, and the following conclusions can be made: 1. Contrast-enhanced US could be considered an indispensable part of percutaneous ablation of Bmode-invisible or poorly visible ablation targets because in up to 75% to 100% of cases, CEUS identified and thereby made it possible to ablate previously invisible tumors; furthermore, CEUS identified additional tumors that needed ablation in the same setting in up to 13% of patients. 2. A CEUS evaluation immediately after the procedure could be used to detect incomplete ablations and allow retreatment within the same session in up to 50% or more. This feature is important, suggesting that using CEUS assessment immediately after ablation may substantially reduce the residual tumor rate after thermal ablation and at the same time reduce patient exposure to ionizing radiation and nephrotoxic contrast agents. 3. Contrast-enhanced US could provide similar accuracy as CT and MRI in follow-up evaluations of individual ablation targets. However, if follow-up is intended also to serve as an evaluation for the occurrence of tumors elsewhere, CT or MRI must be performed parallel to what is done during staging.
Although our literature search identified no randomized or multicenter studies in this section, there were more than 3 level 2 single-center studies (Table 2) performed in a set of nonconsecutive patients, all of whom had undergone both the diagnostic test (CEUS) and the reference standard (US, CT, or MRI) for all 3 of these indications; thus, a grade of recommendation of A can be assigned to these uses of CEUS, according to the criteria in Table 1 .
Contrast-Enhanced US for Intracavitary Use and Miscellaneous Indications
A total of 12 studies (all case series) [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] fall into this miscellaneous section, which includes 4 categories of CEUS assisted procedures: (1) US-guided abscess drainage; (2) US-guided percutaneous nephrostomy; (3) USguided biliary interventions; and (4) hepatic and splenic hemorrhage. In the first 3 categories, a diluted contrast solution (ie, 0.1 mL of SonoVue in 20 mL of saline) is injected directly in the catheter or needle to visualize the exact location of the cavity or tissue around the catheter or needle tip: so-called intracavitary CEUS.
Ultrasound-Guided Abscess Drainage
Two studies described the intracavitary use of CEUS in percutaneous drainage of abdominal and pelvic abscesses. 60, 63 In the largest of these studies, Ignee et al 63 reported 100% placement success (visualization of the catheter or needle) in 71 drainage procedures (69 catheter drainages and 2 needle drainages), in which CEUS provided important additional information with an impact on the procedure in 34 of 71 (48%) of cases: namely, undrained compartments in 24 cases and communication with physiologic cavities in 10 cases. The Figure 8 . Intracavitary CEUS during percutaneous drainage of a left lower quadrant abscess in a 45-year-old male patient. Diluted SonoVue had been injected into the abscess catheter, which is partly visualized with US. In the abscess cavity, a few minor defects are shown, probably due to debris.
benefit of intracavitary CEUS, including catheter/needle control, was confirmed in a smaller series reporting on 28 drainage procedures. 60 Figure 8 and Video 7 show intracavitary CEUS during percutaneous drainage of a left lower quadrant abscess. In Figure 9 and Video 8, intracavitary CEUS during percutaneous drainage of a liver abscess shows communication to the biliary system and free passage through the choledochal duct.
Ultrasound-Guided Percutaneous Nephrostomy
In 2 series of 45 and 47 CEUS-guided percutaneous nephrostomies, respectively, successful catheter placement was reported in 100%. 59, 69 Very remarkable and with great clinical potential, the latter study included only patients with nondilated pelvises, whereas the former study reported that CEUS could show the site of obstruction (renal pelvis, ureter, or urinary bladder) in all cases. Figure 10 and Video 9 show CEUS pyelography replacing an x-ray procedure during US-guided percutaneous nephrostomy.
Ultrasound-Guided Biliary Interventions
The use of transhepatic intrabiliary CEUS has been reported in 4 case series. 61, 62, 67, 70 In the 3 largest series, 80, 38, and 58 cases, respectively, were included, and successful needle and/or catheter positions were reported, with a success rate of 100% in all 3 studies. 62, 67, 70 Furthermore, CEUS showed the correct degree of obstruction (complete or incomplete) in 77 of 80 and 37 of 38 cases and correct visualization of the Figure 9 . Intracavitary CEUS during percutaneous drainage of a liver abscess in a 62-year-old female patient shows communication with the biliary system and free passage through the choledochal duct. Note that on B-mode imaging on the left, the abscess appears echogenic, and it is impossible to tell that it is a cavity, whereas on CEUS imaging on the right, it is clearly shown. A, This initial part of the procedure shows contrast filling of the catheter and the liver abscess cavity. B, After filling the abscess cavity with diluted SonoVue, communication between the liver abscess cavity and biliary system is shown, and free passage through the choledochal duct can be observed.
level of the biliary obstruction (intrahepatic or extrahepatic) in 100% of the cases in the first 2 studies, 62, 67 whereas the third study 70 reported a differentiated result, with 100% accuracy for determining the level of hilar obstruction and 93.3% for extrahepatic obstruction. Interestingly, in that study, the accuracy of CEUS for determining the cause of obstruction was 93.1% (54 of 58), whereas that of percutaneous transhepatic cholangiography was 79.3% (46 of 58; P 5 .031). Figure 11 and Video 10 show CEUS cholangiography replacing an x-ray procedure during percutaneous transhepatic catheter placement in a patient with a Klatskin tumor.
Hepatic and Splenic Hemorrhage
Intravenous use of CEUS to detect and guide percutaneous treatment of splenic and hepatic hemorrhage or lesions after trauma or biopsy has been reported in 4 series, [64] [65] [66] 68 but only in 2 series was another imaging technique (CT) used as the reference standard, which resulted in a detection rate of 100% in both. 64, 65 Three of the studies reported on CEUS-guided percutaneous treatment of hemorrhage. 64, 65, 68 In 1 study, bleeding successfully resolved with thermal ablation in 4 of 5 cases. 68 In the other 2 studies, injection of hemocoagulase in 1 or 2 attempts was reported as successful in 100% in series of 88 and 6 cases, respectively. 64, 65 In Figure 12 and Video 11, intravenous CEUS shows ongoing bleeding from the puncture side on the liver surface immediately after US-guided percutaneous microwave ablation of colorectal cancer metastasis. When bleeding ceases, it is shown how closely coagulated blood resembles liver parenchyma on B-mode US and at the same time how clearly coagulated blood and liver parenchyma differ on a simultaneous CEUS image in a split-screen appearance.
Contrast-Enhanced US for Intracavitary Use and Miscellaneous Indications: Conclusions
The above-mentioned indications are interesting, since a potential alternative to contrast fluoroscopy has been introduced, with advantages such as the lack of patient exposure to ionizing radiation or nephrotoxic contrast agents and, at the same time, the potential for bedside use. These indications include procedures such as fistulography for an abscess diagnostic workup (Figures 8  and 9 and Videos 7 and 8), pyelography ( Figure 10 and Video 9), and cholangiography ( Figure 11 and Video 10). Regarding the use of CEUS as a substitute for percutaneous transhepatic cholangiography, 3 case series reported 100% agreement with fluoroscopy; thus, the technique can be recommended on the basis of good evidence (Table 1) . Contrast-enhanced US has the potential to substantially reduce patient exposure to ionizing radiation in percutaneous transhepatic cholangiography and drainage procedures, and it could be used as a substitute for fluoroscopy for diagnosis and treatment in many of these procedures.
For other indications in this section, comparative studies (CEUS versus non-CEUS or CEUS versus conventional x-ray techniques) that critically evaluate the use of CEUS in these patient groups are still lacking. Figure 10 . Contrast-enhanced US pyelography replacing an x-ray procedure during US-guided percutaneous nephrostomy in 40-yearold female patient with an obstructed ureter. A, Contrast-enhanced US shows that diluted SonoVue has been injected into the nephrostomy catheter, which was visualized with US. The exact location of the catheter tip is not obvious at this point. B, After instillation of additional diluted SonoVue into the nephrostomy catheter, the entire renal pelvis and calyxes are clearly visualized, confirming correct placement of the catheter.
Finally, detection and potential target-directed percutaneous treatment of ongoing intra-abdominal bleeding guided by CEUS may become a useful alternative to transfusion or open surgery (Figure 12 and Video 11). The quality assessment indicated grade of recommendation of A for CEUS-guided percutaneous transhepatic cholangiography and a grade of C for the other indications described in this section (Table 2 ), according to the definitions provided in Table 1 .
Discussion
This study was conducted to map the use of techniques and investigate the evidence behind the many indications for the use of CEUS in relation to percutaneous interventional procedures. Our systematic review identified and analyzed a total of 55 articles in the 3 clinical categories.
The overall strength of this review is that in the identified articles, all of the indications and techniques presented themselves as obvious and logical approaches to the task at hand, and the reported metrics connected with them such, as the feasibility, success rate, sensitivity, and specificity, were all very high. One specific and very important strength of the review is the identification of a sufficient number of good-quality studies dealing with CEUS related interventional procedures to allow for a grade of recommendation of A for very useful indications. This grade implies that, according to the criteria defined in Table 1 , there is good evidence for recommending the particular use of CEUS in question. The grade of A could be assigned for the following: (1) biopsy of inconspicuous or B-mode-invisible liver metastases or percutaneous ablation targets; (2) ablation-related percutaneous interventions, especially intraprocedural, immediate postprocedural, and regular ablation follow-up; and (3) CEUS-guided percutaneous transhepatic cholangiography. These are very important features with potentially practical and frequently useful impact. For example, US-guided biopsy of liver metastases is an excellent tool used in many institutions every day all over the world, but if a target lesion seen on another imaging modality is invisible with conventional US, the procedure cannot be performed. If, however, the lesion becomes visible after administration of a US contrast agent, the biopsy can easily be performed and guided by CEUS. Likewise, biopsies can be directed to avoid necrotic tissue when sampling suspected lesions and the other way around, viable tissue (ie, skip lesions that need further treatment during the course of a percutaneous tumor ablation procedure) may be diagnosed.
There were, however, also limitations to the review, primarily due to the high degree of heterogeneity in both the designs and reported metrics of the included studies. This factor implies that the comparability and thus also the derived ability to draw conclusions based on the scientific data are limited. The consequence of this limitation is that the available data did not allow for conduction of a meta-analysis, which, because of the heterogeneity, may have become misleading. An additional Figure 11 . Contrast-enhanced US cholangiography replacing an x-ray procedure during percutaneous transhepatic cholangiography catheter placement in a 55-year-old male patient with a Klatskin tumor. The image shows diluted SonoVue injected into the catheter. B-mode image on left vaguely shows a few bile ducts. Contrast-enhanced US image on right clearly shows peripherally located, contrast-filled dilated biliary ducts.There is no contrast filling of the central biliary ductal system due to compression from the Klatskin tumor.
limitation was the low quality of evidence, with most of the studies being retrospective and either case series or case-control series with smaller numbers of patients. The explanation for this relative shortage of scientific evidence may be the fact that once these CEUS-guided interventional techniques are developed and made known to the medical community, they immediately become widely accepted because the benefits are obvious. Thus, there is little motivation to conduct more clinical trials.
The prospects of CEUS are very promising and may continue to expand the field of interventional US, as exemplified by the beneficial use of CEUS in combination with fusion imaging in recent reports. 71, 72 At its present stage, CEUS may play a role in many aspects of the daily routine in an interventional US unit and may Figure 12 . Intravenous CEUS showing ongoing bleeding from the puncture side on the liver surface immediately after US-guided percutaneous microwave ablation of colorectal liver metastasis. A, Image shows active bleeding. Notice how explicitly conspicuous the fresh bleeding appears on CEUS imaging (right image) and, at the same time, how explicitly inconspicuous the bleeding per se is on conventional B-mode imaging (left image). The sole information from B-mode imaging is the presence of free fluid, which of course in the actual situation would indicate bleeding but not provide information on whether the bleeding is still going on. B, The bleeding could also be seen with contrast-enhanced color Doppler US, although much less detailed and conspicuous. C, Within a few minutes, the bleeding ceased without any treatment. Notice how closely coagulated blood resembles liver parenchyma on B-mode imaging (left image) and, at the same time, how explicitly clearly coagulated blood and liver parenchyma differ on simultaneous CEUS imaging (right image) in the split-screen appearance.
be of decisive importance in the diagnosis of bleeding as a complication of interventional procedures and especially for evaluating whether the bleeding has ceased; furthermore, it can be helpful in guiding percutaneous treatment of the hemorrhage. This utility is supported by the literature as well as personal experience from our own institutions; however, metadata are lacking, and prospective multicenter studies with comparisons to conventional techniques and preferably with a randomized design are warranted. Contrast-enhanced US characterization of focal liver lesions probably will continue to reduce the need for traditional US-guided interventions such as biopsies. However, at the same time, as indicated by the 2 newly published fusion imaging articles, 71, 72 CEUS has the potential to extend the use of interventional US with new indications.
In conclusion, based on good evidence, CEUS can be recommended as the first choice for percutaneous biopsy or ablation of inconspicuous or B-mode-invisible tumors, for immediate postablation response evaluations and potential reablations, for ablation follow-up, and for percutaneous transhepatic cholangiography and drainage procedures. In addition, numerous already-established and emerging techniques involving CEUS are being used and under ongoing evaluation.
